Medications

J&J loses key tuberculosis drug patent in India

India's Patent Office rejected on Thursday US pharmaceutical giant Johnson and Johnson's application to extend its patent on a key tuberculosis treatment, allowing local companies to make cheaper generic versions.

Diseases, Conditions, Syndromes

XBB.1.5 could be dominant in Europe soon: health agency

Omicron subvariant XBB.1.5, which now accounts for a quarter of US Covid-19 cases, could become the dominant strain in Europe within a few months, the EU's disease agency said Friday.

page 6 from 40